Highly selective cyclooxygenase-1 (COX-1) inhibitor (IC50
values are 0.009 and 6.3 μ
M for COX-1 and COX-2 respectively). Inhibits COX-1-derived platelet thromboxane B2
, gastric PGE2
and dermal PDE2
production. Significantly reduces ovarian surface epithelial tumor growth in vivo
. Orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer.
Daikoku et al.
Cancer Res., 2005;65:3735
COX inhibition and NSAID-induced gastric damage - roles in various pathogenic events.
Takeuchi et al.
Pharmacological analysis of cyclooxygenase-1 in inflammation.
Smith et al.
Proc Natl Acad Sci U S A, 1998;95:13313